PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.

Nanami GotohYusuke MinatoTakayuki SaitohNoriyuki TakahashiTetsuhiro KasamatsuKana SoumaTsukasa OdaTakumi HoshinoToru SakuraTakuma IshizakiHiroaki ShimizuMakiko TakizawaAkihiko YokohamaNorifumi TsukamotoHiroshi HandaHirokazu Murakami

Published in: European journal of haematology (2020)

PARP1 V762A polymorphism may be an independent prognostic factor for MDS, and a predictive biomarker for MDS treatment.

Keyphrases

prognostic factors
dna damage
dna repair
combination therapy
oxidative stress